Drug Trial Radar · NCT06651970
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 4, 2025
Primary completion
Sep 30, 2032
Study completion Sep 30, 2032
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Fortrea; CALYX Inc.; eResearch Technology, Inc.; CISCRP
- First posted
- Oct 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a global Phase IV, open-label, randomised study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally \[po\], twice daily \[bd\]) compared to investigator's choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. Patients with moderate to severe cardiac impairment will include those with moderate to severe cardiac conditions, who may have been excluded from previous acalabrutinib clinical trials and in whom the safety of acalabrutinib was not systematically assessed. The study is planned to take place in approximately 25 centres globally. The study will be conducted in centres that have established close collaboration between the Haematology and Cardiology divisions, preferably with a cardio-oncologist on the team. An IDMC will be responsible for making recommendations for study continuation.
Conditions
- Chronic Lymphocytic Leukaemia
- Moderate to Severe Cardiac Impairment
Interventions
AcalabrutinibDrug
Acalabrutinib Monotherapy
Investigator's choice of treatmentOther
control arm treatment type will be defined by the PI prior to randomisation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety endpoints 1: To evaluate the incidence of CV (CardioVascular) adverse events leading to drug discontinuation after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
- Safety endpoints 2: To evaluate the duration on treatment prior to drug discontinuation due to CV adverse events after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
- Safety endpoints 3: To evaluate the incidence of life threatening and fatal cardiac events of interest after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
- Safety endpoints 4: To evaluate the frequency of grade≥3 Adverse events after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
- Safety endpoints 5: To evaluate the frequency of AESI per Acalabrutinib IB after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
- Safety endpoints 6: To evaluate the rate of discontinuation due to non-CV adverse events after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
- Safety endpoints 7: To evaluate the rate of any serious adverse event after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
Locations
23 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Charlotte, North Carolina · Withdrawn
Research Site
Columbus, Ohio · Recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Brno, Czechia · Recruiting
Research Site
Hradec Králové, Czechia · Withdrawn
Research Site
Prague, Czechia · Recruiting
Research Site
Cagliari, Italy · Recruiting
Research Site
Florence, Italy · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Pavia, Italy · Recruiting
Research Site
Perugia, Italy · Recruiting
Research Site
Krakow, Poland · Recruiting
Research Site
Poznan, Poland · Recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Madrid, Spain · Recruiting
Research Site
Seville, Spain · Recruiting
Research Site
Bournemouth, United Kingdom · Withdrawn
Research Site
Oxford, United Kingdom · Recruiting
Research Site
Plymouth, United Kingdom · Recruiting
Research Site
Romford, United Kingdom · Withdrawn
Research Site
Stockton, United Kingdom · Withdrawn
Research Site
Sutton Coldfield, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.